Silo Pharma OTC Stock Executives
| SILO Stock | USD 1.15 0.05 4.17% |
Silo Pharma employs about 3 people. The company is managed by 3 executives with a total tenure of roughly 7 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive. Analysis of Silo Pharma's management performance can provide insight into the firm performance.
| Eric Weisblum Chairman President Chairman |
Silo |
Silo Pharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.2486) % which means that it has lost $0.2486 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4397) %, meaning that it created substantial loss on money invested by shareholders. Silo Pharma's management efficiency ratios could be used to measure how well Silo Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Silo Pharma Workforce Comparison
Silo Pharma is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 587. Silo Pharma maintains roughly 3.0 in number of employees contributing less than 1% to equities under Health Care industry.
Silo Pharma Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Silo Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Silo Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Silo Pharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Wasserman Adam C over six months ago Insider Trading | ||
Eric Weisblum over six months ago Acquisition by Eric Weisblum of 400 shares of Silo Pharma at 2.03 subject to Rule 16b-3 | ||
Eric Weisblum over six months ago Acquisition by Eric Weisblum of 3408 shares of Silo Pharma at 1.94 subject to Rule 16b-3 | ||
Eric Weisblum over six months ago Purchase by Eric Weisblum of 500 shares of Silo Pharma | ||
Eric Weisblum over six months ago Purchase by Eric Weisblum of 200 shares of Silo Pharma | ||
Eric Weisblum over six months ago Purchase by Eric Weisblum of 600 shares of Silo Pharma | ||
Eric Weisblum over six months ago Purchase by Eric Weisblum of 1000 shares of Silo Pharma | ||
Eric Weisblum over six months ago Purchase by Eric Weisblum of 400 shares of Silo Pharma |
Silo Pharma Notable Stakeholders
A Silo Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Silo Pharma often face trade-offs trying to please all of them. Silo Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Silo Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Eric Weisblum | President Chairman | Profile | |
| MD MBA | Vice Development | Profile | |
| Daniel Ryweck | Chief Officer | Profile |
About Silo Pharma Management Performance
The success or failure of an entity such as Silo Pharma often depends on how effective the management is. Silo Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Silo management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Silo management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Inc., a developmental stage biopharmaceutical company, focuses on merging traditional therapeutics with psychedelic research. Silo Pharma, Inc. was incorporated in 2010 and is headquartered in Englewood Cliffs, New Jersey. Silo Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2 people.
The data published in Silo Pharma's official financial statements typically reflect Silo Pharma's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Silo Pharma's quantitative information. For example, before you start analyzing numbers published by Silo accountants, it's essential to understand Silo Pharma's liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.
Silo Pharma Workforce Analysis
Traditionally, organizations such as Silo Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Silo Pharma within its industry.Silo Pharma Manpower Efficiency
Return on Silo Pharma Manpower
| Revenue Per Employee | 24K | |
| Revenue Per Executive | 24K | |
| Net Loss Per Employee | 1.2M | |
| Net Loss Per Executive | 1.2M | |
| Working Capital Per Employee | 2.3M | |
| Working Capital Per Executive | 2.3M |
Other Information on Investing in Silo OTC Stock
Silo Pharma financial ratios help investors to determine whether Silo OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Silo with respect to the benefits of owning Silo Pharma security.